News of Note—NIH Zika vaccine trial, VBI Vaccines and more


Here is some other vaccine news of note for the week:

> The National Institutes of Health started a first-in-human study of a NIAID-developed live attenuated Zika virus vaccine candidate. Release

> VBI Vaccines appointed Christopher McNulty as its chief financial officer and head of business development. Release

> The Securities and Exchange Commission decided against further action after an investigation into possible securities law violations at Sinovac. Release

> BiondVax has moved manufacturing for its universal flu vaccine candidate to a new facility in the Jerusalem Bio Park. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.